Cingulate Inc (CING)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $62.53M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cingulate Inc (CING) Competitors
The companies most similar to Cingulate are Cognition Therapeutics (CGTX), Instil Bio (TIL) and NextCure (NXTC). By market cap, Cingulate ranks 7th of the 13 companies on this page; Cellectis SA (CLLS) is the largest at $118.86M.
Peer Comparison
CING's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Cingulate (CING) | $62.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cognition Therapeutics Inc (CGTX) | $64.65M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Mink Therapeutics Inc (INKT) | $47.95M | N/A | 236.3x | 0.0% | N/A | 0.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Cardiff Oncology Inc (CRDF) | $56.49M | N/A | 115.5x | 0.0% | N/A | -14.1% | 0.00% |
| Nkarta Inc (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Corbus Pharmaceuticals Holding (CRBP) | $69.86M | N/A | 13.9x | 0.0% | -106.7% | -100.0% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| Cassava Sciences Inc (SAVA) | $114.97M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Peer median | $60.57M | N/A | 68.5x | 0.0% | -90.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Cingulate, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Cognition Therapeutics Inc (CGTX) | Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting... | CGTX competitors |
| Instil Bio Inc. (TIL) | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| Mink Therapeutics Inc (INKT) | MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic... | INKT competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Cardiff Oncology Inc (CRDF) | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. | CRDF competitors |
| Nkarta Inc (NKTX) | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. | NKTX competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Corbus Pharmaceuticals Holding (CRBP) | Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target... | CRBP competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
| Cassava Sciences Inc (SAVA) | Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas. | |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
Frequently Asked Questions About CING
Who are Cingulate's main competitors?
The companies most similar to Cingulate include Cognition Therapeutics (CGTX), Instil Bio (TIL), NextCure (NXTC), Mink Therapeutics (INKT) and ImageneBio (IMA), listed from the closest match.
Who is Cingulate's biggest competitor?
Cellectis SA (CLLS) is the largest of the similar companies at $118.86M; Cognition Therapeutics (CGTX) is the closest match by business profile, size, sector and industry.
How does CING stock compare with its competitors?
CING's net margin is 0.0% against a peer median of 0.0%.
Which of Cingulate's competitors pays a higher dividend?
Cingulate pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Cingulate bigger than its competitors?
No. Cingulate is 7th by market cap among the 13 companies on this page; the largest is Cellectis SA (CLLS) at $118.86M.
CING pages: Overview, Earnings, Forecast, Financials, Competitors